| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:12050258 | IVTH | 0.000000001 - 0.00001 M | 0.00000003 - 0.0000003 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000000001 - 0.00001 M | 0.00000003 - 0.0000003 M | Increased hCG levels | Reproductive endocrine-mediated perturbations | |
| PMID:15276081 | IVR | 1 mg/kg | 1 mg/kg | Affects skeletal development | Developmental endocrine-mediated perturbations |
| IVR | 1 mg/kg | 1 mg/kg | Decreased Alkaline phosphatase (ALP) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:15337578 | IVR | 15 mg/kg | 15 mg/kg | Decreased prostate weights | Reproductive endocrine-mediated perturbations |
| IVR | 15 mg/kg | 15 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 15 mg/kg | 15 mg/kg | Decreased weights of epididymis | Reproductive endocrine-mediated perturbations | |
| IVR | 15 mg/kg | 15 mg/kg | Alterations in preputial separation | Reproductive endocrine-mediated perturbations | |
| IVR | 15 mg/kg | 15 mg/kg | Decreased spleen weights | Immunological endocrine-mediated perturbations | |
| IVR | 15 mg/kg | 15 mg/kg | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 15 mg/kg | 15 mg/kg | Decreased weights of adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 15 mg/kg | 15 mg/kg | Decreased thymus gland weights | Immunological endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Increased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Decreased weights of epididymis | Reproductive endocrine-mediated perturbations | |
| PMID:16996190 | IVTH | 0.000000001 - 0.00000001 M | 0.00000001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| PMID:20399831 | IVR | 10 mg/kg | 10 mg/kg | Increase in Thyrotropin-releasing hormone (TRH) levels | Metabolic endocrine-mediated perturbations |
| IVR | 50 mg/kg | 50 mg/kg | Increase in Thyrotropin-releasing hormone (TRH) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Affects catecholamine biosynthesis | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Decrease in Thyrotropin-releasing hormone (TRH) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Increase in Thyrotropin-releasing hormone (TRH) levels | Metabolic endocrine-mediated perturbations | |
| PMID:22563546 | IVR | 10 mg/kg | 10 mg/kg | Induce apoptosis of ovarian follicles | Reproductive endocrine-mediated perturbations |
| IVR | 10 mg/kg | 10 mg/kg | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| PMID:22852853 | IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Alteration in vaginal morphology | Reproductive endocrine-mediated perturbations |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:24516040 | IVR | 100 mg/L/kg | 100 mg/L/kg | Affects testicular morphology | Reproductive endocrine-mediated perturbations |
| IVR | 100 mg/L/kg | 100 mg/L/kg | Affects steroid metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/L/kg | 100 mg/L/kg | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/L/kg | 100 mg/L/kg | Affects the normal functioning of reproductive system | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/L/kg | 100 mg/L/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/L/kg | 100 mg/L/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/L/kg | 100 mg/L/kg | Testicular atrophy | Reproductive endocrine-mediated perturbations | |
| IVR | 150 mg/L/kg | 150 mg/L/kg | Affects steroid metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 150 mg/L/kg | 150 mg/L/kg | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 150 mg/L/kg | 150 mg/L/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 150 mg/L/kg | 150 mg/L/kg | Testicular atrophy | Reproductive endocrine-mediated perturbations | |
| IVR | 150 mg/L/kg | 150 mg/L/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 150 mg/L/kg | 150 mg/L/kg | Affects testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 150 mg/L/kg | 150 mg/L/kg | Affects the normal functioning of reproductive system | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/L/kg | - | No significant effects observed | - | |
| PMID:25092173 | IVR | 5 mg/kg | 5 mg/kg | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| IVR | 5 mg/kg | 5 mg/kg | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| PMID:25465476 | IVTH | 0.000000001 - 0.0000001 M | 0.00000001 - 0.0000001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000000001 - 0.0000001 M | 0.00000001 - 0.0000001 M | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.000000001 - 0.0000001 M | 0.00000001 - 0.0000001 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:25909344 | IVTH | 0.0000001 M | 0.0000001 M | Affects embryonic development | Developmental endocrine-mediated perturbations |
| IVTH | 0.0000001 M | 0.0000001 M | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| PMID:26961604 | IVTH | 0.0000001 M | 0.0000001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:28180948 | IVTH | 0.00000005 - 0.0000002 M | 0.00000005 - 0.0000002 M | Elevated insulin levels | Metabolic endocrine-mediated perturbations |
| IVR | 0.025 mg/kg/day | 0.025 mg/kg/day | Elevated insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.025 mg/kg/day | 0.025 mg/kg/day | Impaired glucose tolerance | Metabolic endocrine-mediated perturbations | |
| IVR | 0.025 mg/kg/day | 0.025 mg/kg/day | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| PMID:29549738 | IVTH | 0.00000001 M | 0.00000001 M | Decreased aldosterone levels | Metabolic endocrine-mediated perturbations |
| IVTH | 0.0000001 M | 0.0000001 M | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 M | 0.0000001 M | Decrease in cortisol levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.0000001 M | 0.0000001 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 M | 0.0000001 M | Decreased aldosterone levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.00000005 M | 0.00000005 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00000005 M | 0.00000005 M | Decrease in cortisol levels | Neurological endocrine-mediated perturbations | |
| PMID:29580985 | IVTH | 0.00000001 M | 0.00000001 M | Affects placental function | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000001 M | 0.0000001 M | Affects placental function | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000000001 M | 0.0000000001 M | Affects placental function | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000000001 M | 0.000000001 M | Affects placental function | Reproductive endocrine-mediated perturbations | |
| PMID:29636531 | IVR | 0.25 mg/kg | 0.25 mg/kg | Oxidative stress in pancreas | Metabolic endocrine-mediated perturbations |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Reduced insulin levels | Metabolic endocrine-mediated perturbations | |
| PMID:29902746 | IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Decrease in Thyrotropin-releasing hormone (TRH) levels | Metabolic endocrine-mediated perturbations |
| IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0002 mg/kg/day | 0.0002 mg/kg/day | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0002 mg/kg/day | 0.0002 mg/kg/day | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0002 mg/kg/day | 0.0002 mg/kg/day | Decrease in Thyrotropin-releasing hormone (TRH) levels | Metabolic endocrine-mediated perturbations | |
| PMID:29908848 | IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Decreased estrogen levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| PMID:30045567 | IVTH | 0.0000001 M | 0.0000001 M | Affects lipid metabolism | Metabolic endocrine-mediated perturbations |
| IVTH | 0.0000001 M | 0.0000001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000005 M | - | No significant effects observed | - | |
| IVTH | 0.0000005 M | - | No significant effects observed | - | |
| IVTH | 0.000001 M | - | No significant effects observed | - | |
| IVTH | 0.00000001 M | - | No significant effects observed | - | |
| IVTH | 0.00000005 M | - | No significant effects observed | - | |
| PMID:30078105 | IVR | 0.025 mg/kg | 0.025 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:30172001 | IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Alterations in immune responses | Immunological endocrine-mediated perturbations |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| PMID:31129395 | IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Increased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Increased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Decreased Sex hormone-binding globulin (SHBG) levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00001 mg/kg/day | 0.00001 mg/kg/day | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00001 mg/kg/day | 0.00001 mg/kg/day | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00001 mg/kg/day | 0.00001 mg/kg/day | Decreased Sex hormone-binding globulin (SHBG) levels | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.